2023年CSCO胃癌诊疗指南更新解读:转移性胃癌靶向治疗  

CSCO clinical guidelines for diagnosis and treatment of gastric cancer:2023 update on targeted therapy for metastatic gastric cancer

作　　者：关文龙 王风华[1] Guan Wenlong;Wang Fenghua(Department of Medical Oncology,Sun Yat-sen University Cancer Center,State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Guangzhou 510060,China)

机构地区：[1]中山大学肿瘤防治中心肿瘤内科,华南肿瘤学国家重点实验室,肿瘤医学省部共建协同创新中心,广东广州510060

出　　处：《实用肿瘤杂志》2023年第4期301-304,共4页Journal of Practical Oncology

摘　　要：中国临床肿瘤学会(Chinese Society of Clinical Oncology,CSCO)胃癌诊疗指南每年更新,融合国内外最新的临床研究进展,关注中国人群研究数据和新药在中国适应证的获批,以期临床诊疗更加符合我国胃癌国情和贴近本国临床实践,对中国临床医师及广大胃癌患者有着重要意义。胃癌靶向治疗不断取得突破,包括新靶点的识别和开发、新型靶向药物的不断涌现以及以靶向药物为基础的联合治疗策略的不断拓展等。2023年CSCO指南针对转移性胃癌靶向治疗的更新主要体现在2个方面:(1)经典靶点的新型靶向药物取得突破,代表药物为人表皮生长因子受体2(human epidermal growth factor receptor 2,HER2)的抗体偶联药物(antibody-drug conjugate,ADC);(2)针对新靶点的靶向药物的兴起,代表药物为针对Claudin18.2的单克隆抗体。本文将对2023年指南的转移性胃癌靶向治疗部分的主要内容更新进行解读。The Chinese Society of Clinical Oncology(CSCO)guidelines for the diagnosis and treatment of gastric cancer are updated annually.To make the clinical practice more in line with local conditions,the guidelines summarize the latest progress worldwide,focuse on the evidence of the Chinese population and the approval of new therapies in China,which are of great significance to Chinese clinicians and gastric cancer patients.There have been many breakthroughs in targeted therapies for gastric cancer,including the identification of new potential targets,the emergence of novel targeted agents,and new combination strategies of targeted therapies.The update of targeted therapy for metastatic gastric cancer in the latest guidelines mainly focuses on two aspects:(1)the new targeted agents for classical targets,represented by the human epidermal growth factor receptor 2 antibody-drug conjugates(HER2-ADCs);(2)the emergence of other biomarker-targeted therapy,represented by the monoclonal antibody against Claudin18.2.This article provides an interpretation of the updates in the targeted therapy section of the latest guidelines for metastatic gastric cancer.

关 键 词：胃癌 靶向治疗 抗体偶联药物 Claudin18.2 人表皮生长因子受体2 

分 类 号：R735.2[医药卫生—肿瘤]